AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Stock Symbol: ABBV
Stock Exchange: NYSE
People. Passion. Possibilities. Those three simple words mean everything at AbbVie, where patients always come first. So do cutting-edge science and innovation, which fuel our expanding pipeline as we take on the world's toughest health challenges in oncology, immunology, liver disease, women's health and beyond. Together, we strive to make a difference for patients around the world. For more visit: www.abbvie.com.
867 articles with AbbVie
-
Privately-held Tizona Therapeutics snagged $105 million in upfront cash as its cancer antibody TTX-030 is the centerpiece of a collaborative effort with Illinois-based AbbVie.
-
AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39
1/3/2019
Initiation of clinical studies with TTX-030 is targeted in Q1 2019
-
AbbVie to Host Fourth-Quarter and Full-Year 2018 Earnings Conference Call
1/3/2019
AbbVie will announce its fourth-quarter and full-year 2018 financial results on Friday, January 25, 2019 before the market opens.
-
AbbVie closed out 2018 by striking a nearly $1 billion licensing deal for India-based Lupin Limited’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.
-
Readers' Picks: Top 10 Stories of 2018
12/28/2018
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more. -
Lupin and AbbVie Announce Partnership to Develop and Commercialize Novel Oncology Drug to Treat Hematological Cancers
12/24/2018
Lupin Limited and AbbVie Inc., today announced that AbbVie has licensed Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.
-
AbbVie Submits New Drug Application to U.S. FDA and Marketing Authorization Application to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis
12/20/2018
Regulatory applications supported by robust SELECT Phase 3 program evaluating more than 4,000 patients with moderate to severe rheumatoid arthritis
-
AbbVie to Present at the 37th Annual J.P. Morgan Healthcare Conference
12/20/2018
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the 37th annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019. Michael Severino, M.D., Vice Chairman and President, will present at 10:00 a.m. Central time (8:00 a.m. Pacific time).
-
AbbVie and Voluntis to Develop Companion Digital Therapeutics
12/19/2018
Voluntis (Paris:VTX) (Euronext Paris, Mnemo: VTX - ISIN: FR0004183960), a company specialized in digital therapeutics, announces today that it has entered into a collaboration with AbbVie, a research-based global biopharmaceutical company, to enhance patient care coordination in immunology with innovative digital therapeutic software.
-
The new structure creates four top managers who will report directly to the company CEO. All other executives will report to those managers.
-
At 24 weeks, the study met its primary endpoint. Lilly's Taltz demonstrated superiority against AbbVie's Humira, the best-selling drug in the world, in improving the signs and symptoms of active PsA.
-
AbbVie Announces Executive Leadership Changes
12/17/2018
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced a new Executive Leadership Team structure designed to streamline its organizational structure and support its long-term growth strategy.
-
BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance
12/14/2018
BioArctic AB announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. Federal Trade Commission (FTC) clearance to license BioArctic's alpha-synuclein antibody portfolio for Parkinson's disease and other potential indications to AbbVie.
-
AbbVie Inc. Announces $5 Billion Increase to Stock Repurchase Program
12/13/2018
The board of directors of AbbVie Inc. has authorized a $5 billion increase to AbbVie's existing stock repurchase program.
-
Winter and the Holidays are right around the corner, but don't stop your job search! Check out the top companies who are looking for candidates like you right now!
-
With the closure of another year just weeks ahead, this time of year is one that many people use to take a look behind and see what lessons were learned over the past 12 months. For the world of biopharma, it’s also important to see what lessons have been learned.
-
Christmas came a little early for St. Jude Children’s Research Hospital in the form of a $50 million contribution from pharma giant AbbVie – the largest single contribution made to the famed hospital.
-
The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.
-
Illinois-based AbbVie halted a Phase III trial evaluating Rovalpituzumab Tesirine (Rova-T) as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.
-
Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted
12/5/2018
Independent Data Monitoring Committee responsible for ongoing review of study data recommended enrollment be stopped